company background image
RB0 logo

REGENXBIO DB:RB0 Stock Report

Last Price

€7.05

Market Cap

€361.8m

7D

-9.6%

1Y

-57.5%

Updated

23 Dec, 2024

Data

Company Financials +

RB0 Stock Overview

A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. More details

RB0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

REGENXBIO Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for REGENXBIO
Historical stock prices
Current Share PriceUS$7.05
52 Week HighUS$23.60
52 Week LowUS$7.05
Beta1.24
1 Month Change-18.50%
3 Month Change-32.21%
1 Year Change-57.53%
3 Year Change-76.80%
5 Year Change-80.42%
Change since IPO-67.38%

Recent News & Updates

Recent updates

Shareholder Returns

RB0DE BiotechsDE Market
7D-9.6%-3.5%-2.0%
1Y-57.5%-14.7%6.9%

Return vs Industry: RB0 underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: RB0 underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is RB0's price volatile compared to industry and market?
RB0 volatility
RB0 Average Weekly Movement11.5%
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: RB0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: RB0's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2008344Curran Simpsonwww.regenxbio.com

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

REGENXBIO Inc. Fundamentals Summary

How do REGENXBIO's earnings and revenue compare to its market cap?
RB0 fundamental statistics
Market cap€361.83m
Earnings (TTM)-€228.87m
Revenue (TTM)€80.82m

4.5x

P/S Ratio

-1.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RB0 income statement (TTM)
RevenueUS$84.33m
Cost of RevenueUS$249.31m
Gross Profit-US$164.98m
Other ExpensesUS$73.82m
Earnings-US$238.80m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-4.82
Gross Margin-195.65%
Net Profit Margin-283.19%
Debt/Equity Ratio20.5%

How did RB0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:12
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

REGENXBIO Inc. is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Huidong WangBarclays
Alec StranahanBofA Global Research